Fresenius Medical will acquire all of NxStage’s outstanding shares valued a $30 per share, or about $2 billion.
NxStage’s board approved the transaction. The deal is subject to approval from NxStage stockholders, regulatory approvals and additional closing conditions.
Fresenius projects the transaction will close in 2018.
More articles on transactions and valuation:
Piedmont Healthcare opens 27 retail clinics in Atlanta Walgreens stores
Baylor Scott & White now co-owner of Texas Spine & Joint Hospital
University of Chicago Medicine partners with Community Hospital of Indiana to treat high-risk pregnancies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.